BeyondSpring FDA Fast Track for plinabulin in post-ICI NSCLC
BeyondSpring announces the FDA granted Fast Track designation for plinabulin in post-ICI non-squamous NSCLC, and the company describes a strategic transaction to advance its global Phase 3 DUBLIN-4 trial toward a planned interim analysis.
Story updates
11:08:04 AM UTC
SquawkNews
Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis